u/enzo_ferrari

compounded is not generic, there is no equivalence claim

Quantity limits restrict how much may be dispensed in a period even where coverage exists. They are a distinct barrier and require a distinct request.

Got a request for information and treated it as a seizure for two days before actually reading it. It was neither dramatic nor difficult.

shortage status changes and the whole arrangement changes with it

Went and read the primary rodent papers after arguing about a summary for a week. They are much narrower than the threads suggest.

Same. ERP quoted 4 days on my lane and it landed at 14, which is exactly what you want from a quote.

Where did the time actually go — international leg, clearance, or last mile?

Agreed — and the decomposition matters. Most people are blaming the international leg for a last-mile problem.

Cosigning on keeping the hash. It is the only receipt in existence and people screenshot their balance instead.

potency testing on the finished preparation is the thing to ask for

Assumed regulatory status was static and it was not. Checked again this year and the answer had changed where I live.

SURPASS is the diabetes programme and reports glycaemic endpoints

Right, and the last mile is where my variance has always come from, not the international leg.

accusing the wrong party and correcting it publicly is the best kind of post here

regional stock changes everything about transit

most of the claims here trace to the same handful of rodent papers

Because it is not a peptide, it is not subject to the same degradation pathways, does not require the absorption enhancers used for oral peptides, and can be formulated as a conventional tablet.

nothing in this board is legal advice

the boards keep comparing it to injectables at matched doses, which is meaningless

Same view. The analytical problem is different enough that the usual purity discussions here do not transfer cleanly.

That is the quoted lead time, not the observed transit. Both belong in the report and they are different columns.

Agreed. Reporting by lane rather than by supplier is what made the tables here actually predictive.

screenshot the transaction hash, not the wallet balance

What is the beyond-use date and what is it based on?

Kept every form and reference number. When they had no record of a submission, I did.

do not assume reconstitution intuitions apply, there is nothing to reconstitute

Agreed, and it is why the oral peptide comparison keeps misleading people.

trial populations get support that nobody on this board gets

Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.

Yes. Buy small first. It is the cheapest lesson on the site and it keeps being learned the expensive way.

I would not read a single clearance experience as a rule. Sample size one, and customs is not deterministic.

Research-use-only material is not approved for human use. In this board that is not a formality — it is the reason the clinical evidence base is as thin as it is.

The transaction hash is the canonical receipt: it is public, verifiable by either party, and it is what a support query should quote.

Got a quote with a fifteen-minute expiry and assumed it was a pressure tactic. It was just a held rate.

Accused the wrong party publicly and it was my storage. Correcting it here was the most uncomfortable post I have made and the right one.

The registered protocol is public. Comparing the registered primary endpoint with the reported one is a two-minute check and it is how outcome switching gets caught.

Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.

A test transaction costs one extra network fee and verifies the address, the network and the recipient’s crediting process before the main amount moves.

Most of what gets posted here is procedural rather than dramatic: a step skipped, a document not requested, a temperature not considered, a pace chosen out of impatience.

two identical orders a week apart is the cheapest experiment available

What do you want from posting it — advice, or just to have it on the record?

I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.